ELITE LABS INC
GenericsELITE LABS INC is a generic drug manufacturer focused on Cardiovascular.
Upcoming FDA Decisions
Full Calendar →ELITE LABS INC's Key Drugs
ELITE LABS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ELITE LABS INC's Recent FDA Approvals
New NDA/BLA approvals for ELITE LABS INC over the last two years — novel drugs only, excluding generics and label supplements.
ELITE LABS INC's Therapeutic Areas
ELITE LABS INC's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ELITE LABS INC's Top Competitors
ELITE LABS INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ELITE LABS INC Pipeline Snapshot
Active clinical trials for ELITE LABS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1997-05-30
- Latest
- 2026-06-18
- Applications
- 22